---

Role of topical ophthalmic solutions (0.1%) olopatadine hydrochloride and (0.05%) epinastine hydrochlloride in vernal keratoconjuntivitis

---

Original Article

Author Details : Tahir Husain Ansari, Yusuf Rizvi*

Volume : 6, Issue : 3, Year : 2020

Article Page : 374-378

https://doi.org/10.18231/j.ijceo.2020.080

Suggest article by email

Get Permission

---

Abstract

Background: VKC is of great concern to all ophthalmologists in India because it is found to be quite
common in our country and the tropical countries and if untreated it can lead to sight threatening
complications.
Materials and Methods: The present study was carried out in fourty patients who attended the outpatient
department ophthalmology, Darbhanga Medical College and Hospital, Laheriasarai. The study was carried
out from July 2007 Dec 2008. Forty patients with symptoms of VKC (ocular itching, ropy discharge
discharge, papillary hypertrophy, gelatinous thickening and (horner-trantas spots) were selected and
included in our study.
Results: Olopatadine treated group- Means score of itching at 0, 14, 28, 42 days in olopatadine treated eye
were 3.2, 2.1, 1.2, and 0.4 respectively having value P<0> score at same stages in Placebo eye were 3.2, 3.1, 3 and 2.6 having p value >0.05. Olopatadine Treated
Group-Mean scores of ropy discharge at 0, 14, 28, and 42 days in were 2.9, 2.1, 1.3 and 0.6 respectively
having P value <0> eye were 2.9, 2.8, 2.7 and 2.4 respectively having P value >0.05.
Conclusion: It was concluded that the present study shown that both olopatadine and epinastine is effective
and reducing itching and ropy discharge of VKC as compared to placebo.

Keywords: Epinastine hydrochlloride, Itching, Olopatadine hydrochloride, Placebo, Vernal keratoconjuntivitis, Ropy discharge.

How to cite : Ansari T H , Rizvi Y , Role of topical ophthalmic solutions (0.1%) olopatadine hydrochloride and (0.05%) epinastine hydrochlloride in vernal keratoconjuntivitis. Indian J Clin Exp Ophthalmol 2020;6(3):374-378

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.